Clearing away neurodegenerative disease

PRECISION MEDICINE TO PRESERVE NEURONS

Caraway Therapeutics is an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons. It is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components (autophagy), an exciting new focus for potential therapeutics. Caraway has a rigorous, scientific product engine with multiple approaches, using genetically defined targets to find potential treatments related to these processes.

Urgent, Unmet Medical Need

Targeted Approach

Leveraging Advances in Neuroscience

Neurodegenerative diseases represent an urgent and expanding unmet medical need. Caraway’s approach to developing targeted treatments leverages the body’s natural ability to identify toxic cellular materials and enhances their clearance, preventing loss of neurons. By increasing lysosomal flux, Caraway’s small molecules can stimulate clearance of dysfunctional cellular components.

News

December 3, 2019

Caraway Therapeutics Expands Leadership Team With Appointment of Martin D. Williams as Chief Executive Officer and Cristina Csimma, PharmD, MHP, as Chair of the Board of Directors

October 10, 2019

Rheostat Therapeutics Announces Rebrand to Caraway Therapeutics and New Kendall Square Office

Our Team

Solutions to complex problems require an unique combination of rigor and creativity. The Caraway team drives our development programs forward by bringing passion and precision to our work every day.